Lyme borreliosis is the most common tick-borne disease in the United States and Europe. It is caused by spirochetes of the Borrelia burgdorferi species complex which are transmitted by ticks of the genus Ixodes. This paper presents a review of the studies published about Lyme borreliosis in Europe and in Italy. Seroepidemiologic studies have been conducted in various European countries concerning patients, groups at risk and general population. The distribution of LB in Europe is very variable and the risk is associated with occupational and recreational activities in forested areas and with residence in rural area. Taking the limitations of seroprevalence methods into account, it is evident that the prevalence of Lyme borreliosis varies considerably in different European countries, with an overall increasing prevalence from west to east in central-eastern Europe, a gradient of decreasing incidence in Spain and Greece and from north to south in Italy.
Lyme borreliosis is the most common tick-borne disease in the United States and Europe. It is caused by spirochetes of the Borrelia burgdorferi species complex which are transmitted by ticks of the genus Ixodes (1).
B. burgdorferi sensu lato is a Gram-negative spirochete divided into at least 11 different genomic species. To date, four of these species are known to be human pathogens: B. burgdorferi sensu stricto, B. garinii, and B. afzelii, and B. valaisiana (2) . Recently a new genospecies, designated B. spielmani, has been isolated from patients and ticks. These studies indicate that B. spielmani may also cause human Lyme borreliosis (3) (4) (5) . The principal vectors are 1. ricinus in Europe, I. persulcatus in Eurasia and parts of Asia, and 1. scapularis and 1. pacijicus in North America (east and west, respectively) (6) .
Borrelia can survive and multiply in vertebrate reservoirs, from which they are taken up by ticks.
In Europe small mammals such as mice and voles provide reservoirs for B. afzelii, B. burgdorferi sensu stricto and B. garinii, and birds are resevoirs for B. garinii and B. valaisiana (6) . Lyme borreliosis is a multi-system disorder characterized by a skin lesion, the "Erythema Chronicum Migrans" (ECM), which can be followed, weeks or months later, by neurological, cardiac or arthritic manifestations (1). In Europe, the disease occurs in localized areas of the British Isles and throughout continental Europe, with relatively high frequency in southern Scandinavia, the Netherlands, parts of Germany and in eastern European countries, such as Austria and Slovenia. Endemic levels are relatively low in France, Switzerland, Italy, Spain, Portugal and the Balkan countries. The rates of reported cases decrease from south to north in Scandinavia and from north to south in Italy (7) . In Italy the first case was diagnosed in 1985 in a middle-aged woman, a farmer in the neighbourhood of Genoa (8) , and the first strain of B. burgdorferi was isolated in Trieste in 1989 and has been designated BITS I (9) .
Surveillance statistics in Europe are based on varying case criteria and on disparate systems of data collection. Moreover, the existence of several pathogenic B. burgdorferi genospecies complicates surveillance. One of the most common ways of evaluating the circulation of an infectious agent is to search for specific antibodies in a susceptible population at high risk of exposure. Published studies have mainly relied on measurement of the seroprevalence of antibodies to B. burgdorferi among occupational groups compared with controls. This paper presents a review of the studies published about Lyme borreliosis in Europe and in Italy.
Descriptive SlInJnJWY ofpublished literature Seroepidemiologic studies have been conducted in various European countries concerning patients, groups at risk and general population (Table I ). In Sweden, sera of 253 individuals at risk and 249 clerks were tested by Elisa. The prevalence of B. burgdorferi antibodies was 7.6% in the risk group vs. 5.3% in the clerks (10) .
A study conducted in Aland Island, a group of islands in the Baltic Sea between Finland and Sweden, among 3,748 healthy population found that 19.7% of all the sera was positive for B. burgdorferi IgG antibodies. The authors have come to the conclusion that this area is strongly endemic for Lyme borreliosis (11).
The prevalence of antibodies to B. burgdorferi in rheumatology patients in an endemic area of Russia revealed that from 6.6 to 11.9% had anti-B. burgdorferi antibodies (12) . In the Netherlands antibodies to B. burgdorferi were assessed in 312 (13) .
In Poland the sera of blood donors and people professionally exposed to tick bites were analyzed. The seroprevalence was 38% in forestry workers and 12% in blood donors. The authors concluded that Poland is an endemic territory of Lyme borreliosis (14) . In fact, another study conducted in Poland shows that Lyme borreliosis is increasing, with 655 cases reported in 1997 and 3,574 in 2003 (15). Two serological studies carried out in Austria on at risk population in two different area revealed that 42% and 10% had anti-B. burgdorferi antibodies (16) (17) . Orienteers from all parts of Switzerland (n = 416) were included in a longitudinal study for Lyme borreliosis. The seroprevalence was 28. 1% (18) . In Germany blood samples of 4,368 forestry workers in the State of Baden-Wuerttemberg (B-W), south-western Germany, were tested for the presence of antibodies against B. burgdorferi s.l. The seroprevalence rates ranged from 18% to 52% (19) .
A retrospective study on Lyme borreliosis conducted in France in 2003 on 16,176 subjects revealed the presence of anti-B. burgdorferi antibodies in 9% for IgG and in 29% for IgM (20) . Another study was carried out among forestry workers -the prevalence of seropositive was 15.2% (21) . Of the seroprevalence of antibodies against B. burgdorferi s.l. among the Slovenian forestry workers, 23.8% was greater than among the indoor workers (9.7%) (22) . In a seroepidemiologic study performed in northwest Croatia, general population sera were analyzed and 7.5% of the sera samples were positive (23) . Another study was carried out in Croatia to compare the prevalence of antibodies against B. burgdorferi among forestry workers and general population. The IgG antibodies were found in 4.7% from the group of forestry workers and in 3% from the second group (24) .
The seroprevalence of Lyme disease is very low in Greece. Among the general population it was reported that the frequency of IgG and/or IgM B. burgdorferi specific antibodies was 5.9% (25) . In an other study conducted on the young male adult population the prevalence was 3.27% (26) . To evaluate B. burgdorferi antibody prevalence in the province of Madrid a total of 1825 serum samples were tested. Specific antibodies were found in 3.45% of the samples (27) .
In our country various cases have been recognized from some regions of Northern Italy such as Friuli-Venezia-Giulia, Veneto and Liguria, while sporadic cases have been reported in other regions (Table II) . In Friuli-Venezia-Giulia, the seropositivity for Lyme borreliosis was 23.2% among forestry rangers (28) . In Veneto, 1,115 patients with clinical symptoms suggestive of Lyme disease were examined. 113 (10%) had IgG and IgM antibodies anti-B. burgdorferi by ELISA and 2.5% were confirmed by WB (29) . In Liguria 1,550 patients with suspected Lyme borreliosis were examined. Antibodies against B. burgdorferi were detected in 184 (11.8%)/1550 (30) . In Emilia a study was conducted on 613 patients between 1990 and 1994. Only one sample 0.2%, showed significant antibody titres by IFA (31) . In Tuscany, a total of 412 blood samples were taken from agricultural and forestry workers and 365 blood donors served as controls. Antibodies against B. burgdorferi were more frequent among the workers than in the control group (7.8% vs. 4.9%) (32) . In Lazio a total of 1,050 serum samples collected from patients presenting clinical manifestations typical of Lyme borreliosis and 330 serum samples from blood donors, as control group, were tested for IgG antibodies to B. burgdorferi. Of the patients, 34 (3.2%) sera were found positive, while 7 (1.5%) sera of the control group were positive (33) . In Abruzzo 22 national park workers and 50 national park inhabitants were controlled for the presence of antibodies to B. burgdorferi. The seroprevalence was -9.1 % in the park workers and 0% in the control group (34) .
Another study was conducted in Lazio and Abruzzo on 212 workers at risk for tick bites and 180 individuals who were not considered at risk. The seropositivity was higher in the risk group (2.4%) than in the control group (0.5%) (35) .
In Umbria 454 serum samples obtained from patients, in part hospitalized and in part outpatients, were analyzed for antibodies to B. burgdorferi. 13 sera (2.8%) resulted positive (36) . In Campania 55 children with arthritis and 60 asymptomatic children were tested. Significant titres were observed in 9.1% of the children with arthritis. None of the control group showed significative antibody titres (37) . In Sicily 182 sera of healthy subjects were tested. 9 (4.9%) were positive for IgG by Elisa and 7 (3.8%) by IFA. All sera were negative for IgM by IFA and Elisa (38) .
Our study comprised 175 subjects at risk and 145 subjects not at risk, inhabitants of Campania and Sicily, were analyzed. The seropositivity was higher in the risk group (13.7%) than in the control group (2.1%) (35) . In Calabria our work conducted on 300 rheumatologic patients reported a positivity rate of 7.3% by Elisa (39) .
In Sardinia a seroepidemiologic study carried out on 441 teen-agers estimated a seroprevalence of 6.1% (40) .
CONCLUSIONS
The distribution of Lyme borreliosis in Europe is very variable and the risk is associated with occupational and recreational activities in forested areas and with residence in rural areas. Although many studies have documented the occurrence of Lyme disease, comparisons of the data continue to be difficult. In fact, data obtained from various European laboratories are often not directly comparable because the serological tests used to detect antibodies to B. burgdorferi are not yet standardized. To date, Lyme disease has been documented in many occupational groups, including forestry workers, farmers, veterinarians, orienteers and outdoor workers in general.
The range of antibodies to B. burgdorferi is highest in Northern and Central Europe and the lowest in Southern Europe. The highest differences reported in the same nation, between antibody percentages in forestry workers and in control subjects, were found in Poland (from 38% to 12%) and in Slovenia (from 23.8% to 9.7%); the lowest differences were found in Croatia (from 4.7% to 3%) and Sweden (from 7.6% to 5.3%) (Table I) . In Northern Europe the seroprevalence of antibodies to B. burgdorferi is higher in Finland (19.7% among general population) and lower in Sweden (5.3% among clerks of a risk area). In Central Europe the incidence is higher in Austria (42% among risk subjects) and Poland (38% among forestry workers) and lower in the Netherlands (14% in forestry workers and 1.4% in control group). In Southern Europe we have the highest incidence in Slovenia, (23.8% among forestry workers and 9.7% among indoor workers), while we have the lowest incidence in Greece (3% among general population). In Italy the seroprevalence of antibodies to B. burgdorferi in patients seems to vary from the highest in Northern Italy (Liguria 11.8%) to the lowest in Central Italy (Emilia 0.2%), while in at-risk subjects it seems to vary, from the highest in Northern Italy (Friuli 23.2%) to the lowest in Central Italy (Lazio 2.4%). Of the general population they vary from the highest in Toscana (4.9%) to the lowest in Campania (0%) ( Table II) .
Taking the limitations of seroprevalence methods into account, it is evident that the prevalence of Lyme borreliosis varies considerably in different European countries with an overal1 increasing prevalence from west to east in central-eastern Europe, a gradient of decreasing incidence in Spain and Greece and from north to south in Italy. Further seroepidemiological studies are necessary, especially in a high-risk population, in order to take suitable measures to prevent tick exposure. Since no safe or effective vaccine against Lyme disease has been licensed in Europe, where other pathogenic Borrelia genospecies are predominant, prevention should be based on unspecific measures to reduce the risk of tick bites and on appropriate management in the case of a bite. Preventive measures include avoiding exposure by limiting outdoor activities in tick-infested locations, using tick repellents, tucking in clothing, and frequently inspecting skin for early detection and the correct removal of ticks (32) .
